Skip to main content
Erschienen in: Journal of Translational Medicine 1/2020

Open Access 01.12.2020 | Letter to the Editor

Survival differences by ethnicity among patients diagnosed with bladder cancer

verfasst von: Boda Guo, Ming Liu

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
This comment refers to the article available at https://​doi.​org/​10.​1186/​s12967-020-02308-w.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BC
Bladder cancer
Dear Editor,
We read the study by Fang et al. [1] with great interest and would like to congratulate the authors for their superb study. The authors compared the oncologic outcomes of bladder cancer (BC) of different ethnicities, which may aid in clinical decision-making. As such, there are a few points that we would like to bring up.
1.
Their study included patients with primary BC but did not exclude multiple primary cancers. However, another SEER-based study showed BC patients were at a significantly higher risk of developing a second malignancy, which may affect patients’ survival [2].
 
2.
BC surgery in the SEER database includes transurethral resection of bladder, partial cystectomy and complete cystectomy, etc. It would be more meaningful to stratify patients according to the type of surgery that they received; in this way, readers can easily see which surgical treatment improves BC patient’s survival better.
 
3.
Some of the patients included in the analysis received radiotherapy or chemotherapy. These two types of treatment should be taken into consideration since prior studies showed that both radiotherapy and chemotherapy hold great potential in the management of BC patients [3, 4].
 

Acknowledgements

None.

Disclaimers

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Not applicable.
Not applicable.

Competing interests

Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145 (Epub 2020/04/02. Eng).CrossRef Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145 (Epub 2020/04/02. Eng).CrossRef
2.
Zurück zum Zitat Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma—a population-based study. Anticancer Res. 2017;37(4):2033–6 (Epub 2017/04/05. Eng).CrossRef Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma—a population-based study. Anticancer Res. 2017;37(4):2033–6 (Epub 2017/04/05. Eng).CrossRef
3.
Zurück zum Zitat Diaz DA, Pollack A, Reis IM, Mahmoud O, Gonzalgo ML, Ishkanian A, et al. Neoadjuvant radiotherapy improves survival in patients with T2b/T3 bladder cancer: a population-based analysis. Clin Genitourin Cancer. 2015;13(4):378–84 (Epub 2015/04/25. Eng).CrossRef Diaz DA, Pollack A, Reis IM, Mahmoud O, Gonzalgo ML, Ishkanian A, et al. Neoadjuvant radiotherapy improves survival in patients with T2b/T3 bladder cancer: a population-based analysis. Clin Genitourin Cancer. 2015;13(4):378–84 (Epub 2015/04/25. Eng).CrossRef
4.
Zurück zum Zitat Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34(8):825–32 (Epub 2016/01/21. Eng).CrossRef Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34(8):825–32 (Epub 2016/01/21. Eng).CrossRef
Metadaten
Titel
Survival differences by ethnicity among patients diagnosed with bladder cancer
verfasst von
Boda Guo
Ming Liu
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2020
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02668-3

Weitere Artikel der Ausgabe 1/2020

Journal of Translational Medicine 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.